CEO SUMMARY: In recent years, annual revenue at Bostwick Laboratories has skyrocketed, reaching $102.8 mil- lion in 2007. Now the company, known for its national uropathology expertise, has filed documents in preparation for an initial public stock offering (IPO). Bostwick Laboratories is the latest success story in anatomic pathology. It hopes to raise $100 million
Bostwick Labs Prepares For Public Stock Offering
By Robert Michel, from the Volume XV No. 4 - March 24, 2008 issue